Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10 - PubMed (original) (raw)

Comparative Study

. 2004 Oct;31(4):395-404.

doi: 10.1165/rcmb.2004-0175OC. Epub 2004 Jun 17.

Affiliations

• PMID: 15205180
• DOI: 10.1165/rcmb.2004-0175OC

Comparative Study

Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10

Andrew M Tager et al. Am J Respir Cell Mol Biol. 2004 Oct.

Abstract

Pulmonary fibrosis is an enigmatic and devastating disease with few treatment options, now thought to result from abnormal wound healing in the lung in response to injury. We have previously noted a role for the chemokine interferon gamma-inducible protein of 10 kD (IP-10)/CXC chemokine ligand 10 in the regulation of cutaneous wound healing, and consequently investigated whether IP-10 regulates pulmonary fibrosis. We found that IP-10 is highly expressed in a mouse model of pulmonary fibrosis induced by bleomycin. IP-10-deficient mice exhibited increased pulmonary fibrosis after administration of bleomycin, suggesting that IP-10 limits the development of fibrosis in this model. Substantial fibroblast chemoattractant and proliferative activities were generated in the lung after bleomycin exposure. IP-10 significantly inhibited fibroblast responses to the chemotactic, but not the proliferative activity generated, suggesting that IP-10 may attenuate fibroblast accumulation in bleomycin-induced pulmonary fibrosis by limiting fibroblast migration. Consistent with this inhibitory activity of IP-10 on fibroblast migration, fibroblast accumulation in the lung after bleomycin exposure was dramatically increased in IP-10-deficient mice compared with wild-type mice. Conversely, transgenic mice overexpressing IP-10 were protected from mortality after bleomycin exposure, and demonstrated decreased fibroblast accumulation in the lung after challenge compared with wild-type mice. Our findings suggest that interruption of fibroblast recruitment may represent a novel therapeutic strategy for pulmonary fibrosis, which could have applicability to a wide range of fibrotic illnesses.

PubMed Disclaimer

Similar articles

• IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis.
  Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM. Keane MP, et al. J Immunol. 1999 Nov 15;163(10):5686-92. J Immunol. 1999. PMID: 10553099
• Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis.
  Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE, Burdick MD, Kunkel SL, Strieter RM. Keane MP, et al. J Immunol. 1999 May 1;162(9):5511-8. J Immunol. 1999. PMID: 10228032
• E- and P-selectins synergistically inhibit bleomycin-induced pulmonary fibrosis.
  Horikawa M, Fujimoto M, Hasegawa M, Matsushita T, Hamaguchi Y, Kawasuji A, Matsushita Y, Fujita T, Ogawa F, Takehara K, Steeber DA, Sato S. Horikawa M, et al. Am J Pathol. 2006 Sep;169(3):740-9. doi: 10.2353/ajpath.2006.060086. Am J Pathol. 2006. PMID: 16936251 Free PMC article.
• The role of CXC chemokines in pulmonary fibrosis.
  Strieter RM, Gomperts BN, Keane MP. Strieter RM, et al. J Clin Invest. 2007 Mar;117(3):549-56. doi: 10.1172/JCI30562. J Clin Invest. 2007. PMID: 17332882 Free PMC article. Review.
• Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis.
  Antoniou KM, Pataka A, Bouros D, Siafakas NM. Antoniou KM, et al. Pulm Pharmacol Ther. 2007;20(5):453-61. doi: 10.1016/j.pupt.2006.01.002. Epub 2006 Mar 3. Pulm Pharmacol Ther. 2007. PMID: 16516512 Review.

Cited by

• Targeted delivery of TGF-β mRNA to lung parenchyma using one-component ionizable amphiphilic Janus Dendrimers.
  Atochina-Vasserman E, Meshanni J, Stevenson E, Zhang D, Sun R, Ona N, Reagan E, Abramova E, Guo CJ, Wilkinson M, Baboo I, Yang Y, Pan L, Maurya D, Percec V, Li Y, Gow A, Weissman D. Atochina-Vasserman E, et al. Res Sq [Preprint]. 2024 Jul 12:rs.3.rs-4656663. doi: 10.21203/rs.3.rs-4656663/v1. Res Sq. 2024. PMID: 39041040 Free PMC article. Preprint.
• Exploring unconventional targets in myofibroblast transdifferentiation outside classical TGF-β signaling in renal fibrosis.
  Lathan R. Lathan R. Front Physiol. 2024 May 14;15:1296504. doi: 10.3389/fphys.2024.1296504. eCollection 2024. Front Physiol. 2024. PMID: 38808357 Free PMC article. Review.
• Chemokine Receptor Profile of T Cells and Progression Rate of Geographic Atrophy Secondary to Age-related Macular Degeneration.
  Martinez Villarruel Hinnerskov J, Krogh Nielsen M, Kai Thomsen A, Steffensen MA, Honoré B, Vorum H, Nissen MH, Sørensen TL. Martinez Villarruel Hinnerskov J, et al. Invest Ophthalmol Vis Sci. 2024 Jan 2;65(1):5. doi: 10.1167/iovs.65.1.5. Invest Ophthalmol Vis Sci. 2024. PMID: 38165703 Free PMC article.
• CXCL10 deficiency limits macrophage infiltration, preserves lung matrix, and enables lung growth in bronchopulmonary dysplasia.
  Hirani DV, Thielen F, Mansouri S, Danopoulos S, Vohlen C, Haznedar-Karakaya P, Mohr J, Wilke R, Selle J, Grosch T, Mizik I, Odenthal M, Alvira CM, Kuiper-Makris C, Pryhuber GS, Pallasch C, van Koningsbruggen-Rietschel S, Al-Alam D, Seeger W, Savai R, Dötsch J, Alejandre Alcazar MA. Hirani DV, et al. Inflamm Regen. 2023 Oct 24;43(1):52. doi: 10.1186/s41232-023-00301-6. Inflamm Regen. 2023. PMID: 37876024 Free PMC article.
• Distribution and chemotactic mechanism of CD4+ T cells in traumatic tracheal stenosis.
  Feng T, Chen Y, Wei J, Tan S, Guangnan L. Feng T, et al. Immun Inflamm Dis. 2023 Aug;11(8):e916. doi: 10.1002/iid3.916. Immun Inflamm Dis. 2023. PMID: 37647429 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)